These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 32634126)

  • 21. Convalescent plasma for COVID-19: Donor demographic factors associated high neutralising antibody titres.
    Mehew J; Johnson R; Roberts D; Griffiths A; Harvala H
    Transfus Med; 2022 Aug; 32(4):327-337. PubMed ID: 35434868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population.
    Yi Z; Ling Y; Zhang X; Chen J; Hu K; Wang Y; Song W; Ying T; Zhang R; Lu H; Yuan Z
    Emerg Microbes Infect; 2020 Dec; 9(1):1988-1996. PubMed ID: 32844713
    [No Abstract]   [Full Text] [Related]  

  • 23. Convalescent Plasma Therapy in Patients With Severe or Life-Threatening COVID-19: A Metadata Analysis.
    Rabelo-da-Ponte FD; Silvello D; Scherer JN; Ayala AR; Klamt F
    J Infect Dis; 2020 Oct; 222(9):1575-1578. PubMed ID: 32777038
    [No Abstract]   [Full Text] [Related]  

  • 24. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
    Bradfute SB; Hurwitz I; Yingling AV; Ye C; Cheng Q; Noonan TP; Raval JS; Sosa NR; Mertz GJ; Perkins DJ; Harkins MS
    J Infect Dis; 2020 Oct; 222(10):1620-1628. PubMed ID: 32779705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays.
    DomBourian MG; Annen K; Huey L; Andersen G; Merkel PA; Jung S; Dominguez SR; Knight V
    J Immunol Methods; 2020 Nov; 486():112837. PubMed ID: 32828791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment for emerging viruses: Convalescent plasma and COVID-19.
    Brown BL; McCullough J
    Transfus Apher Sci; 2020 Jun; 59(3):102790. PubMed ID: 32345485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influential factor and trend of specific IgG antibody titer in coronavirus disease 2019 convalescents.
    Wu C; Liu W; Li G; Zhang Z; Xiao K; LE A
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 45(10):1172-1175. PubMed ID: 33268577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of convalescent plasma therapy in severe COVID-19 patients.
    Duan K; Liu B; Li C; Zhang H; Yu T; Qu J; Zhou M; Chen L; Meng S; Hu Y; Peng C; Yuan M; Huang J; Wang Z; Yu J; Gao X; Wang D; Yu X; Li L; Zhang J; Wu X; Li B; Xu Y; Chen W; Peng Y; Hu Y; Lin L; Liu X; Huang S; Zhou Z; Zhang L; Wang Y; Zhang Z; Deng K; Xia Z; Gong Q; Zhang W; Zheng X; Liu Y; Yang H; Zhou D; Yu D; Hou J; Shi Z; Chen S; Chen Z; Zhang X; Yang X
    Proc Natl Acad Sci U S A; 2020 Apr; 117(17):9490-9496. PubMed ID: 32253318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020.
    Harvala H; Mehew J; Robb ML; Ijaz S; Dicks S; Patel M; Watkins N; Simmonds P; Brooks T; Johnson R; Gopal R; Roberts DJ; Zambon M;
    Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Convalescent Plasma and COVID-19.
    Malani AN; Sherbeck JP; Malani PN
    JAMA; 2020 Aug; 324(5):524. PubMed ID: 32530454
    [No Abstract]   [Full Text] [Related]  

  • 31. Antibody-dependent enhancement and COVID-19: Moving toward acquittal.
    Yager EJ
    Clin Immunol; 2020 Aug; 217():108496. PubMed ID: 32526272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Convalescent Plasma: Promise for COVID-19 Pandemic.
    Sheikh S; Baig MA
    J Coll Physicians Surg Pak; 2020 Jun; 30(6):88. PubMed ID: 32723468
    [No Abstract]   [Full Text] [Related]  

  • 33. Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?
    Xi Y
    Signal Transduct Target Ther; 2020 Sep; 5(1):203. PubMed ID: 32934211
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of coronavirus disease 2019.
    Hung IFN
    Curr Opin HIV AIDS; 2020 Nov; 15(6):336-340. PubMed ID: 33002954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.
    Rojas M; Rodríguez Y; Hernández JC; Díaz-Coronado JC; Vergara JAD; Vélez VP; Mancilla JP; Araujo I; Yepes JT; Ricaurte OB; Pardo-Oviedo JM; Monsalve DM; Acosta-Ampudia Y; Ramírez-Santana C; García PG; Landinez LA; Correales LD; Grass JS; Pérez CR; López GS; Mateus N; Mancera L; Devia RR; Orjuela JE; Parra-Moreno CR; Buitrago AA; Ordoñez IE; Osorio CF; Ballesteros N; Patiño LH; Castañeda S; Muñoz M; Ramírez JD; Bastard P; Gervais A; Bizien L; Casanova JL; Camacho B; Gallo JE; Gómez O; Rojas-Villarraga A; Pérez CE; Manrique R; Mantilla RD; Anaya JM
    BMC Infect Dis; 2022 Jun; 22(1):575. PubMed ID: 35761219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Convalescent plasma in Covid-19: Possible mechanisms of action.
    Rojas M; Rodríguez Y; Monsalve DM; Acosta-Ampudia Y; Camacho B; Gallo JE; Rojas-Villarraga A; Ramírez-Santana C; Díaz-Coronado JC; Manrique R; Mantilla RD; Shoenfeld Y; Anaya JM
    Autoimmun Rev; 2020 Jul; 19(7):102554. PubMed ID: 32380316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients.
    Tremblay D; Seah C; Schneider T; Bhalla S; Feld J; Naymagon L; Wang B; Patel V; Jun T; Jandl T; Rahman F; Liu STH; Aberg JA; Bouvier N;
    Cancer Med; 2020 Nov; 9(22):8571-8578. PubMed ID: 32945149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19.
    Alzoughool F; Alanagreh L
    Int J Risk Saf Med; 2020; 31(2):47-51. PubMed ID: 32310190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment.
    Ouyang J; Isnard S; Lin J; Fombuena B; Peng X; Routy JP; Chen Y
    Front Immunol; 2020; 11():570063. PubMed ID: 33072111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Convalescent plasma treatment for COVID-19: Tempering expectations with the influenza experience.
    Subbarao K; Mordant F; Rudraraju R
    Eur J Immunol; 2020 Oct; 50(10):1447-1453. PubMed ID: 32886952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.